COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
HCQ study #186 of 259
11/12 Post Exposure Prophylaxis study (treated after exposure to the virus)
Simova et al., New Microbes and New Infections, doi:10.1016/j.nmni.2020.100813 (Peer Reviewed)
Hydroxychloroquine for prophylaxis and treatment of COVID-19 in health care workers
Source   PDF   Share   Tweet
100% reduction in cases with HCQ+zinc post-exposure prophylaxis. Brief report for healthcare workers in Bulgaria.
0 cases with treatment vs. 3 for control.
156 treatment patients and 48 control patients.
No serious adverse events. This paper reports on both PEP and early treatment, we have separated the two studies.

Simova et al., 11/12/2020, retrospective, Bulgaria, Europe, peer-reviewed, 5 authors.
risk of COVID-19 case, 92.7% lower, RR 0.07, p = 0.01, treatment 0 of 156 (0.0%), control 3 of 48 (6.2%).

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 259 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit